TTP399

TTP399 is an investigational new drug being developed by vTv Therapeutics for the treatment of type 1 diabetes. It is an orally administered, liver-selective glucokinase activator.

Mechanism of Action[edit | edit source]

TTP399 works by activating glucokinase, a key regulatory enzyme in the liver that plays a significant role in glucose metabolism. When glucose levels are high, glucokinase converts glucose to glucose-6-phosphate, which is then used to produce energy or stored as glycogen. By activating glucokinase, TTP399 increases the rate of glucose metabolism, thereby reducing blood glucose levels.

Clinical Trials[edit | edit source]

TTP399 has undergone several clinical trials to evaluate its safety and efficacy in patients with type 1 diabetes. In a Phase 2 trial, TTP399 demonstrated a statistically significant reduction in HbA1c levels, a key marker of long-term blood glucose control, compared to placebo. The drug was also well-tolerated, with no reports of severe hypoglycemia or diabetic ketoacidosis.

Potential Benefits[edit | edit source]

TTP399 could potentially offer several benefits over existing treatments for type 1 diabetes. As an oral medication, it would be more convenient than injectable insulin. Furthermore, its liver-selectivity could reduce the risk of hypoglycemia, a common side effect of many diabetes medications.

Future Development[edit | edit source]

vTv Therapeutics is currently planning further clinical trials to confirm the efficacy and safety of TTP399 in a larger population of patients with type 1 diabetes.

File:TTP399 structure.png

Chemical structure of TTP399